Re: the latest on gene silencing in vivo

[Guest guest]

so what does that mean?

what do you think:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

cmd=Retrieve & db=pubmed & dopt=Abstract & list_uids=9988491 & query_hl=1

borrelia uses hsp 60. do you think they could make something? are they

worth contacting. i think so but would like your opinion.

this is a sideline but might be very worthwhile. might improve

efficacy of existing treatments. if they could be convinced there was

a market.

> is that the Fab end of a specific antibody fused with a nucleic-acid-

> binding protein carrying siRNA, can effectively get that siRNA into

> cells binding the antibody (by uncertain means). Delivery is the

> biggest problem with gene silencing, so that this works is pretty

damn

> cool.

> PMID 15908939

[Guest guest]

> so what does that mean?

I dono. Some genes make good RNAi targets and others dont, for

unknown reasons. For a good target, gene expression can so far be

reduced about 80%. I have no idea whether the costs of RNAi drugs

would be too too huge but my wild guess would be, no.

But, what human genes would you silence to fight our diseases of

interest? We dont know.

> what do you think:

> http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?

> cmd=Retrieve & db=pubmed & dopt=Abstract & list_uids=9988491 & query_hl=1

>

> borrelia uses hsp 60. do you think they could make something? are

they

> worth contacting. i think so but would like your opinion.

Bacteria wont take up the siRNAs that are the current mainstay of

RNAi. However they do take up Alan Christians siHybrids. But as far

as the possibility of using RNAi agents to fight say Bb - to me it

begs the question of why Bb is obliterated in glass by a variety of

abx whereas this apparantly fails often in vivo.